398 related articles for article (PubMed ID: 33815387)
1. Emerging Therapeutic Strategies to Restore Regulatory T Cell Control of Islet Autoimmunity in Type 1 Diabetes.
Volfson-Sedletsky V; Jones A; Hernandez-Escalante J; Dooms H
Front Immunol; 2021; 12():635767. PubMed ID: 33815387
[TBL] [Abstract][Full Text] [Related]
2. Regulatory T cells prevent transfer of type 1 diabetes in NOD mice only when their antigen is present in vivo.
Tonkin DR; He J; Barbour G; Haskins K
J Immunol; 2008 Oct; 181(7):4516-22. PubMed ID: 18802054
[TBL] [Abstract][Full Text] [Related]
3. Low TCR signal strength induces combined expansion of Th2 and regulatory T cell populations that protect mice from the development of type 1 diabetes.
Turner MS; Isse K; Fischer DK; Turnquist HR; Morel PA
Diabetologia; 2014 Jul; 57(7):1428-36. PubMed ID: 24737163
[TBL] [Abstract][Full Text] [Related]
4. Pancreatic islet autoimmunity.
Boitard C
Presse Med; 2012 Dec; 41(12 P 2):e636-50. PubMed ID: 23182678
[TBL] [Abstract][Full Text] [Related]
5. Generation of human islet-specific regulatory T cells by TCR gene transfer.
Hull CM; Nickolay LE; Estorninho M; Richardson MW; Riley JL; Peakman M; Maher J; Tree TI
J Autoimmun; 2017 May; 79():63-73. PubMed ID: 28117148
[TBL] [Abstract][Full Text] [Related]
6. Proinsulin-specific T regulatory cells may control immune responses in type 1 diabetes: implications for adoptive therapy.
Gliwiński M; Iwaszkiewicz-Grześ D; Wołoszyn-Durkiewicz A; Tarnowska M; Żalińska M; Hennig M; Zielińska H; Dukat-Mazurek A; Zielkowska-Dębska J; Zieliński M; Jaźwińska-Curyłło A; Owczuk R; Jarosz-Chobot P; Bossowski A; Szadkowska A; Młynarski W; Marek-Trzonkowska N; Moszkowska G; Siebert J; Myśliwiec M; Trzonkowski P
BMJ Open Diabetes Res Care; 2020 Feb; 8(1):. PubMed ID: 32098895
[TBL] [Abstract][Full Text] [Related]
7. Stem cell-derived tissue-associated regulatory T cells suppress the activity of pathogenic cells in autoimmune diabetes.
Haque M; Lei F; Xiong X; Das JK; Ren X; Fang D; Salek-Ardakani S; Yang JM; Song J
JCI Insight; 2019 Apr; 4(7):. PubMed ID: 30777937
[TBL] [Abstract][Full Text] [Related]
8. KLRG1 expression identifies short-lived Foxp3
Kornete M; Mason E; Istomine R; Piccirillo CA
Autoimmunity; 2017 Sep; 50(6):354-362. PubMed ID: 28850267
[TBL] [Abstract][Full Text] [Related]
9. Alpha-Lipoic Acid Inhibits Spontaneous Diabetes and Autoimmune Recurrence in Non-Obese Diabetic Mice by Enhancing Differentiation of Regulatory T Cells and Showed Potential for Use in Cell Therapies for the Treatment of Type 1 Diabetes.
Huang SH; Kuo SL; Chen SJ; Lin JR; Chen YW; Hong ZJ; Sytwu HK; Lin GJ
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163121
[TBL] [Abstract][Full Text] [Related]
10. Immunomodulation Followed by Antigen-Specific T
Cabello-Kindelan C; Mackey S; Sands A; Rodriguez J; Vazquez C; Pugliese A; Bayer AL
Diabetes; 2020 Feb; 69(2):215-227. PubMed ID: 31712320
[TBL] [Abstract][Full Text] [Related]
11. A Novel Liposome Formulation Carrying Both an Insulin Peptide and a Ligand for Invariant Natural Killer T Cells Induces Accumulation of Regulatory T Cells to Islets in Nonobese Diabetic Mice.
Akimoto H; Fukuda-Kawaguchi E; Duramad O; Ishii Y; Tanabe K
J Diabetes Res; 2019; 2019():9430473. PubMed ID: 31781669
[TBL] [Abstract][Full Text] [Related]
12. Harnessing the power of regulatory T-cells to control autoimmune diabetes: overview and perspective.
Yu H; Paiva R; Flavell RA
Immunology; 2018 Feb; 153(2):161-170. PubMed ID: 29155454
[TBL] [Abstract][Full Text] [Related]
13. Antigen-Specific Treg Therapy in Type 1 Diabetes - Challenges and Opportunities.
Serr I; Drost F; Schubert B; Daniel C
Front Immunol; 2021; 12():712870. PubMed ID: 34367177
[TBL] [Abstract][Full Text] [Related]
14. Harnessing memory adaptive regulatory T cells to control autoimmunity in type 1 diabetes.
Li CR; Baaten BJ; Bradley LM
J Mol Cell Biol; 2012 Feb; 4(1):38-47. PubMed ID: 22116888
[TBL] [Abstract][Full Text] [Related]
15. Treg Enhancing Therapies to Treat Autoimmune Diseases.
Eggenhuizen PJ; Ng BH; Ooi JD
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32977677
[TBL] [Abstract][Full Text] [Related]
16. Towards antigen-specific Tregs for type 1 diabetes: Construction and functional assessment of pancreatic endocrine marker, HPi2-based chimeric antigen receptor.
Radichev IA; Yoon J; Scott DW; Griffin K; Savinov AY
Cell Immunol; 2020 Dec; 358():104224. PubMed ID: 33068914
[TBL] [Abstract][Full Text] [Related]
17. Customized cell-based treatment options to combat autoimmunity and restore beta-cell function in type 1 diabetes mellitus: current protocols and future perspectives.
Fändrich F; Ungefroren H
Adv Exp Med Biol; 2010; 654():641-65. PubMed ID: 20217518
[TBL] [Abstract][Full Text] [Related]
18. Function, Failure, and the Future Potential of Tregs in Type 1 Diabetes.
Bettini M; Bettini ML
Diabetes; 2021 Jun; 70(6):1211-1219. PubMed ID: 34016597
[TBL] [Abstract][Full Text] [Related]
19. Role of regulatory T cells for the treatment of type 1 diabetes mellitus.
Jaeckel E; Mpofu N; Saal N; Manns MP
Horm Metab Res; 2008 Feb; 40(2):126-36. PubMed ID: 18283631
[TBL] [Abstract][Full Text] [Related]
20. Combination Therapy Using IL-2/IL-2 Monoclonal Antibody Complexes, Rapamycin, and Islet Autoantigen Peptides Increases Regulatory T Cell Frequency and Protects against Spontaneous and Induced Type 1 Diabetes in Nonobese Diabetic Mice.
Manirarora JN; Wei CH
J Immunol; 2015 Dec; 195(11):5203-14. PubMed ID: 26482409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
